Novo’s Denecimig Review Slips After FDA Flags Manufacturing Remediation

The FDA has extended its review of Novo’s investigational hemophilia A drug denecimig, with the company saying the agency cited “ongoing facility remediation activities” as the reason for the delay. Novo said the FDA did not identify any deficiencies related to the drug’s efficacy or safety.

Denecimig, a bispecific antibody that Novo describes as a next-gen factor VIII mimetic, was submitted for FDA review in September 2025. A decision had been slated for the third quarter of this year, but Novo announced the delay on the second day of the fourth quarter. The company said the FDA has not yet provided a new review timeline.

The regulatory issue

Novo said it is working to address the agency’s remediation requests tied to an unnamed manufacturing site. The company also said the manufacturing flag does not affect its other marketed products.

That distinction matters. The delay appears to be about site readiness rather than the drug’s clinical profile, but it still interrupts a late-stage regulatory path and removes visibility on timing until the FDA sets a new date. For companies with specialized biologics, manufacturing can remain a gating factor even after a filing is accepted.

Novo CEO Mike Doustdar said the company is addressing the FDA’s requests “as efficiently as possible” and continuing to work with the agency toward bringing denecimig to patients in the U.S.

The commercial picture

Novo said it is still preparing for a 2027 denecimig launch for hemophilia A in adults and children. The company also said the extended review has no impact on its financial outlook for 2026.

BMO Capital Markets had listed the denecimig decision among seven key catalysts for Novo in a Sept. 9 report and rated it of “medium” importance. The drug is being tested as a prophylactic treatment to prevent bleeding episodes in hemophilia A, and the program is also under evaluation for potential approval by European regulators.

The broader signal is that CMC risk can reshape launch timing without changing the underlying commercial thesis. Novo is keeping its launch planning intact for now, but until remediation is resolved and the FDA issues a new timeline, denecimig remains a regulatory asset with execution risk centered on manufacturing rather than on the drug itself.

The road here

The report places the delay against a backdrop of other Novo manufacturing challenges linked to Novo Holdings’ $16.5 billion buy of Catalent in 2024. Novo then acquired three of Catalent’s fill-finish sites to support demand for Ozempic and Wegovy, while also inheriting customers that Catalent made products for.

Earlier this year, quality problems at an ex-Catalent fill-finish facility in Indiana led Scholar Rock to remove that plant from its application for apitegromab. The FDA had given the site an Official Action Indicated classification, and Scholar Rock later won approval for the product, now sold as Isembyld, after dropping the plant from the filing.